Abemaciclib 1231929-97-7

Product Details

Abeciclib is an oral inhibitor of cyclin-dependent kinase CDK4/6. In HR+, HER2- breast cancer cells, CDK4 and CDK6 promote the phosphorylation of retinoblastoma protein and promote cell cycle progression and cellular hyperplasia. Abemaciclib 1231929-97-7 inhibits Rb phosphorylation and blocks cell progression from G1 to S phase of the cell cycle, resulting in cellular senescence and apoptosis. Accelerates cell cycle progression and cell proliferation.

Approved by the FDA on September 28, 2017, the indication is hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced stage patients who have received endocrine therapy in combination with second-line treatment of fulvestrant Or metastatic breast cancer, or HR+/HER2- advanced or metastatic breast cancer with disease progression after endocrine therapy and chemotherapy as monotherapy.

Health Benefits

• Advanced or metastatic HR+ and HER-2- breast cancer patients.
• For patients with breast cancer whose disease deteriorates after hormone therapy, it can be used in combination with fluprogesterone.
• Early breast cancer patients who received chemotherapy for distant metastasis.
• The combination of abeciclib and an aromatase inhibitor can be used as a first-line hormonal therapy for breast cancer in postmenopausal women.